{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:15:19Z","timestamp":1793531719459,"version":"4.5.0"},"reference-count":43,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100010733","name":"B\u00f8rnecancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As pegylated asparaginase is becoming the preferred first\u2010line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly PEG\u2010asparaginase (where PEG is polyethylene glycol) treatment by measuring serum\n                      <jats:sc>l<\/jats:sc>\n                      \u2010asparaginase activity and formation of anti\u2010PEG\u2010asparaginase antibodies. A total of 97 evaluable patients (1\u201317 years), diagnosed with ALL, and treated according to the NOPHO ALL2008 protocol (where NOPHO is Nordic Society of Paediatric Haematology and Oncology) were included. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG\u2010asparaginase (Oncaspar\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) 1,000 IU\/m\u00b2\/dose, at 2\u2010week or 6\u2010week intervals with a total of 30\u2010week treatment (Clinical trials.gov. no.: NCT00819351).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The pharmacological target of treatment (\n                      <jats:sc>l<\/jats:sc>\n                      \u2010asparaginase activity above 100 IU\/l) was reached in 612 of 652 (94%) samples obtained 14\u00a0\u00b1\u00a02 days after PEG\u2010asparaginase administration. Mean\n                      <jats:sc>l<\/jats:sc>\n                      \u2010asparaginase activity was 338 IU\/l. Six patients had\n                      <jats:sc>l<\/jats:sc>\n                      \u2010asparaginase activity below 50 IU\/l in all samples. A total of 25 patients (26%) developed Immunoglobulin G (IgG) anti\u2010PEG\u2010asparaginase antibodies, but there was no correlation between anti\u2010PEG\u2010asparaginase antibodies and low levels of asparaginase activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We conclude that prolonged first\u2010line biweekly PEG\u2010asparaginase therapy, 1,000 IU\/m\u00b2\/dose was above the pharmacological target in the vast majority of patients. Presence of anti\u2010PEG\u2010asparaginase antibodies was not a predictor of\n                      <jats:sc>l<\/jats:sc>\n                      \u2010asparaginase activity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.26686","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T04:38:40Z","timestamp":1498711120000},"source":"Crossref","is-referenced-by-count":35,"title":["Prolonged first\u2010line PEG\u2010asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol\u2014Pharmacokinetics and antibody formation"],"prefix":"10.1002","volume":"64","author":[{"given":"Louise","family":"Tram Henriksen","sequence":"first","affiliation":[{"name":"Department of Pediatrics Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2695-8391","authenticated-orcid":false,"given":"Sofie","family":"Gottschalk H\u00f8jfeldt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine Copenhagen University Hospital  Copenhagen Denmark"},{"name":"Faculty of Medicine Institute of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Leth","family":"Frandsen","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine Copenhagen University Hospital  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder","family":"Skov Wehner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hans Christian Andersen Children's Hospital \u00a0Odense University Hospital  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schr\u00f8der","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Klug Albertsen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Nordic Society of Pediatric Hematology and Oncology, NOPHO Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.253"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027714"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.251"},{"issue":"1","key":"e_1_2_9_5_1","first-page":"S62","article-title":"Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL\u2010BFM study group from 1981 to 2000","volume":"225","author":"Schrappe M","year":"2013","journal-title":"Klin Padiatr"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636"},{"key":"e_1_2_9_8_1","first-page":"3893","article-title":"Effective dose of L\u2010asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group","volume":"39","author":"Ertel IJ","year":"1979","journal-title":"Cancer Res"},{"key":"e_1_2_9_9_1","first-page":"942","article-title":"L\u2010asparaginase in the treatment of neoplastic diseases in children","volume":"31","author":"Jaffe N","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_9_10_1","first-page":"4363","article-title":"In vitro and in vivo killing of acute lymphoblastic leukemia cells by L\u2010asparaginase","volume":"49","author":"Asselin BL","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685615"},{"key":"e_1_2_9_12_1","first-page":"4554","article-title":"L\u2010asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi R","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00131-1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.17.040177.000525"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-534347"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10096"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367904"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200404000-00002"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.102"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1986"},{"key":"e_1_2_9_22_1","first-page":"24","article-title":"A pharmacological study on pegylated asparaginase used in front\u2010line treatment of children with acute lymphoblastic leukemia","volume":"91","author":"Rizzari C","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00363-0"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25489"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12097"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.09.027"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12733"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12865"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03148.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.019"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245951"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02187.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1780"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.2070"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-381731"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8404"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31822d4d4e"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.162"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403011"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22739"},{"key":"e_1_2_9_42_1","first-page":"1964","article-title":"A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L\u2010asparaginase","volume":"119","author":"Patel N","year":"2009","journal-title":"J Clin Invest"},{"key":"e_1_2_9_43_1","first-page":"2423","article-title":"Asparaginases: biochemical pharmacology and modes of drug resistance","volume":"32","author":"Avramis VI.","year":"2012","journal-title":"Anticancer Res"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000030"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.26686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:53:17Z","timestamp":1695963197000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.26686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/pbc.26686"],"URL":"https:\/\/doi.org\/10.1002\/pbc.26686","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,29]]},"article-number":"e26686"}}